Astrazeneca Plc $AZN Shares Acquired by AMG National Trust Bank

AMG National Trust Bank boosted its position in shares of Astrazeneca Plc (NYSE:AZN) by 8.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,714 shares of the company’s stock after buying an additional 3,731 shares during the quarter. AMG National Trust Bank’s holdings in Astrazeneca were worth $4,294,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of AZN. Brighton Jones LLC lifted its holdings in Astrazeneca by 93.2% in the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after acquiring an additional 2,789 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Astrazeneca by 45.3% in the 1st quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after purchasing an additional 11,690 shares during the last quarter. Amundi grew its stake in shares of Astrazeneca by 54.4% in the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after purchasing an additional 3,618 shares during the last quarter. Jump Financial LLC raised its holdings in shares of Astrazeneca by 898.4% in the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after purchasing an additional 30,125 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its holdings in shares of Astrazeneca by 1.2% in the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock worth $3,259,000 after purchasing an additional 559 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on AZN shares. TD Cowen restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Barclays reaffirmed an “overweight” rating on shares of Astrazeneca in a report on Tuesday, January 6th. Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research note on Saturday, April 4th. Citigroup started coverage on Astrazeneca in a report on Tuesday, January 27th. They issued a “buy” rating on the stock. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $102.67.

Astrazeneca Price Performance

Shares of Astrazeneca stock opened at $187.30 on Tuesday. The stock has a market capitalization of $290.48 billion, a P/E ratio of 32.27, a price-to-earnings-growth ratio of 1.43 and a beta of 0.35. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72. Astrazeneca Plc has a 1 year low of $132.32 and a 1 year high of $212.71.

Astrazeneca Announces Dividend

The business also recently declared a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were given a $1.595 dividend. This represents a dividend yield of 156.0%. The ex-dividend date of this dividend was Friday, February 20th. Astrazeneca’s dividend payout ratio is 74.83%.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.